Responses
Original research
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
Compose a Response to This Article
Other responses
No responses have been published for this article.